How many billions is enough? Prioritizing profits over patients with cystic fibrosis

Affiliations

¹ Department of Pediatrics, Division of Pediatric Pulmonary Medicine, University of California San Francisco, San Francisco, California, USA.
² Department of Pediatrics, Division of Pulmonary Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
³ Department of Pediatrics, Division of Pediatric Pulmonology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire, USA.
⁴ Department of Pediatrics, Division of Pulmonary Medicine, Harvard Medical School, Boston, Massachusetts, USA.
⁵ Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA.

Meghan E McGarry et al. Pediatr Pulmonol. 2023 May.

. 2023 May;58(5):1595-1597.

doi: 10.1002/ppul.26335. Epub 2023 Feb 10.

¹ Department of Pediatrics, Division of Pediatric Pulmonary Medicine, University of California San Francisco, San Francisco, California, USA.
² Department of Pediatrics, Division of Pulmonary Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
³ Department of Pediatrics, Division of Pediatric Pulmonology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire, USA.
⁴ Department of Pediatrics, Division of Pulmonary Medicine, Harvard Medical School, Boston, Massachusetts, USA.
⁵ Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA.

No abstract available

Keywords: cystic fibrosis; ethics; personalized medicine; pharmacotherapy.

Conflict of interest statement

Conflict of Interest: Dr. Sawicki has served on advisory boards for Vertex Pharmaceuticals.

1. Burgel P-R, Durieu I, Chiron R, et al. Rapid improvement after starting elexacaftor–tezacaftor–ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. American journal of respiratory and critical care medicine. 2021;204(1):64–73. - PubMed
1. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. New England Journal of Medicine. 2019;381(19):1809–1819. - PMC - PubMed
1. Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JL. Pregnancy among cystic fibrosis women in the era of CFTR modulators. Journal of Cystic Fibrosis. 2017;16(6):687–694. - PMC - PubMed
1. McGarry ME, Gibb ER, Oates GR, Schechter MS. Left behind: the potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis. Paediatric Respiratory Reviews. 2021; - PMC - PubMed
1. Vertex Reports Third Quarter 2022 Financial Results. Vertex Pharmaceuticals; October 27,2022, https://investors.vrtx.com/news-releases/news-release-details/vertex-rep...